ATAD2B

Across TCGA pan-cancer cohorts, ATAD2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATAD2B data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ATAD2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATAD2B expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where ATAD2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.875	0.610	.014	12	view →
LUAD	DFS	Tertile	II,III,IV	0.655	0.194	.047	2	view →
PDAC	DFS	Median	II,III,IV	0.533	0.328	.045	2	view →
HNSC	DFS	Median	IV	0.595	0.784	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATAD2B–LSCC (OS)

Open the LSCC breakdown →